Nevirapine (1) is a non-nucleoside reverse transcriptase inhibitor marketed for HIV treatment by Boehringer Ingelheim as Viramune since 1996. In vitro studies of nevirapine biotransformation using human liver microsomes demonstrated the formation of five major metabolites. This paper describes the syntheses of these metabolites.
Grozinger, Karl G.,Byrne, Denis P.,Nummy, Laurence J.,Ridges, Michael D.,Salvagno, Annette
p. 229 - 239
(2007/10/03)
More Articles about upstream products of 284686-16-4